Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Stephen J. Forman, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Leslie Popplewell, MD, Maria L Delioukina, MD, Torres Alejandra, MS, Bernadette Pulone, RN, OCN, Eileen P. Smith, MD, Auayporn P. Nademanee, MD, Chatchada Karanes, MD, Paul O'Donnell, MD, PhD, David G. Maloney, MD, PhD, Len Farol, MD, Schickwann Tsai, MD, PhD, Laurie E. Grove, PA-C, Ajay K. Gopal, MD

Blood (2011) 118 (21): 664.

https://doi.org/10.1182/blood.V118.21.664.664

Published: 2011

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

Mark Kirschbaum, MD, Leslie Popplewell, Auayporn P. Nademanee, Vinod Pullarkat, Maria Delioukina, Jasmine M. Zain, Deron Matsuoka, Bernadette Pulone, Paul Frankel, Igor Espinoza-Delgado, MD, Stephen J. Forman, David Gandara, Edward Newman

Blood (2008) 112 (11): 1564.

https://doi.org/10.1182/blood.V112.11.1564.1564

Published: 2008

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study.

Mark H. Kirschbaum, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Vinod Pullarkat, MD, Auayporn P. Nademanee, MD, Maria L. Delioukina, MD, Bernadette Pulone, RN, Deron Matsuoka, BS, Paul Frankel, PhD, Zwiebel A. James, MD, Stephen J. Forman, MD, Edward Newman, PhD, David Gandara, MD

Blood (2007) 110 (11): 2568.

https://doi.org/10.1182/blood.V110.11.2568.2568

Published: 2007

Journal Articles

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Mark H. Kirschbaum, MD, Anthony Selwyn Stein, MD, Joseph Tuscano, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Margaret R. O’Donnell, MD, Chatchada Karanes, MD, John Wright, MD, Bernadette Pulone, RN, Amalia Rincon, Paul Frankel, PhD, Stephen J. Forman, MD, Edward Newman, PhD

Blood (2007) 110 (11): 891.

https://doi.org/10.1182/blood.V110.11.891.891

Published: 2007

Journal Articles

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Mark Kirschbaum, MD, Anthony Selwyn Stein, MD, Joseph Tuscano, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Margaret R. O’Donnell, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, John J. Wright, MD, Bernadette Pulone, RN, Amalia Rincon, MA, Paul Frankel, PhD, Stephen J. Forman, MD, Newman Edward, PhD

Blood (2006) 108 (11): 1948.

https://doi.org/10.1182/blood.V108.11.1948.1948

Published: 2006

NARROW

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only